FYERS
Home
/
Stocks
/
Results
/
IOL Chemicals And Pharmaceuticals Results

IOL Chemicals And Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
--2%12%
--0%36%
21%12%32%94%
9%9%8%8%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
IOLCP
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,901.4₹456833 Cr37.7712.0762.82₹11479 Cr
9,180.5₹245426 Cr83.9134.04128.41₹2568 Cr
4,860.5₹187320 Cr85.8916.7297.06₹2163 Cr
1,131₹113217 Cr25.099.4262.53₹5040 Cr
1,382.9₹112212 Cr33.299.7757.87₹3879 Cr
1,851.3₹101155 Cr92.526.829.25₹889 Cr
2,123.2₹97626 Cr17.6630.95154.36₹5333 Cr
2,336.5₹96859 Cr47.4213.7571.08₹1913 Cr
1,162.4₹96406 Cr29.925.3263.99₹4196 Cr
1,658₹93614 Cr25.2217.9596.84₹3505 Cr
200.87₹5753 Cr34.222.198.51₹138 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
₹756 Cr₹619 Cr₹580 Cr₹568 Cr₹552 Cr₹528 Cr₹523 Cr₹526 Cr₹502 Cr₹504 Cr₹520 Cr₹545 Cr₹563 Cr₹587 Cr₹523 Cr₹541 Cr₹565 Cr₹572 Cr
₹8 Cr₹2 Cr₹5 Cr₹7 Cr₹7 Cr₹5 Cr₹4 Cr₹6 Cr₹7 Cr₹8 Cr₹8 Cr₹7 Cr₹7 Cr₹9 Cr₹7 Cr₹5 Cr₹5 Cr₹7 Cr
₹764 Cr₹621 Cr₹586 Cr₹574 Cr₹559 Cr₹532 Cr₹527 Cr₹532 Cr₹510 Cr₹511 Cr₹529 Cr₹552 Cr₹570 Cr₹596 Cr₹530 Cr₹546 Cr₹570 Cr₹579 Cr
₹674 Cr₹547 Cr₹543 Cr₹530 Cr₹509 Cr₹484 Cr₹495 Cr₹502 Cr₹468 Cr₹471 Cr₹492 Cr₹497 Cr₹505 Cr₹504 Cr₹493 Cr₹521 Cr₹520 Cr₹538 Cr
₹112 Cr₹94 Cr₹63 Cr₹64 Cr₹70 Cr₹67 Cr₹51 Cr₹48 Cr₹58 Cr₹57 Cr₹53 Cr₹71 Cr₹80 Cr₹104 Cr₹49 Cr₹37 Cr₹61 Cr₹52 Cr
₹4 Cr₹3 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹2 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹5 Cr₹5 Cr₹4 Cr₹3 Cr₹2 Cr
₹87 Cr₹71 Cr₹28 Cr₹40 Cr₹46 Cr₹45 Cr₹28 Cr₹26 Cr₹40 Cr₹37 Cr₹32 Cr₹51 Cr₹61 Cr₹87 Cr₹33 Cr₹22 Cr₹47 Cr₹39 Cr
₹64 Cr₹53 Cr₹21 Cr₹30 Cr₹34 Cr₹31 Cr₹21 Cr₹19 Cr₹30 Cr₹28 Cr₹23 Cr₹38 Cr₹46 Cr₹65 Cr₹24 Cr₹16 Cr₹35 Cr₹30 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
—————
₹59 Cr₹59 Cr₹59 Cr₹59 Cr₹59 Cr
₹1740 Cr₹1629 Cr₹1553 Cr₹1449 Cr₹1334 Cr
₹1740 Cr₹1629 Cr₹1553 Cr₹1449 Cr₹1334 Cr
₹1799 Cr₹1688 Cr₹1612 Cr₹1508 Cr₹1392 Cr
₹85 Cr₹78 Cr₹66 Cr₹56 Cr₹53 Cr
₹2 Cr₹0₹4 L₹14 L₹43 L
₹11 Cr₹7 Cr₹7 Cr₹2 Cr₹3 Cr
₹98 Cr₹85 Cr₹73 Cr₹58 Cr₹57 Cr
—————
₹483 Cr₹428 Cr₹469 Cr₹314 Cr₹409 Cr
₹70 Cr₹63 Cr₹55 Cr₹54 Cr₹54 Cr
₹132 Cr₹117 Cr₹33 Cr₹80 Cr₹43 Cr
₹49 Cr₹31 Cr₹40 Cr₹54 Cr₹69 Cr
₹733 Cr₹639 Cr₹597 Cr₹503 Cr₹575 Cr
₹2630 Cr₹2411 Cr₹2282 Cr₹2068 Cr₹2024 Cr
₹6 Cr₹6 Cr₹6 Cr₹5 Cr₹18 L
₹132 Cr₹117 Cr₹33 Cr₹80 Cr₹43 Cr
—————
₹1632 Cr₹1544 Cr₹1236 Cr₹995 Cr₹762 Cr
₹451 Cr₹374 Cr₹303 Cr₹243 Cr₹201 Cr
₹1182 Cr₹1171 Cr₹933 Cr₹752 Cr₹561 Cr
₹94 Cr₹21 Cr₹100 Cr₹81 Cr₹102 Cr
₹17 Cr₹17 Cr₹17 Cr₹17 Cr₹0
₹17 Cr₹17 Cr₹17 Cr₹17 Cr₹0
₹20 Cr₹12 Cr₹24 Cr₹10 Cr₹11 Cr
₹45 Cr₹9 Cr₹50 Cr₹233 Cr₹205 Cr
₹1359 Cr₹1231 Cr₹1125 Cr₹1102 Cr₹881 Cr
—————
₹4 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr
₹371 Cr₹361 Cr₹425 Cr₹326 Cr₹410 Cr
₹603 Cr₹514 Cr₹471 Cr₹505 Cr₹470 Cr
₹198 Cr₹208 Cr₹143 Cr₹22 Cr₹140 Cr
₹30 Cr₹27 Cr₹25 Cr₹30 Cr₹31 Cr
₹65 Cr₹67 Cr₹90 Cr₹82 Cr₹90 Cr
₹1271 Cr₹1180 Cr₹1157 Cr₹967 Cr₹1143 Cr
₹537 Cr₹541 Cr₹560 Cr₹464 Cr₹567 Cr
₹2630 Cr₹2411 Cr₹2282 Cr₹2068 Cr₹2024 Cr
₹61₹57₹274₹257₹237
₹61₹57₹55₹257₹237

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
₹184 Cr₹138 Cr₹182 Cr₹189 Cr₹225 Cr
₹85 Cr₹80 Cr₹60 Cr₹44 Cr₹33 Cr
-₹17 Cr-₹21 Cr₹90 Cr-₹64 Cr-₹102 Cr
₹252 Cr₹197 Cr₹332 Cr₹169 Cr₹156 Cr
₹214 Cr₹179 Cr₹290 Cr₹122 Cr₹93 Cr
-₹198 Cr-₹154 Cr-₹191 Cr-₹120 Cr-₹121 Cr
-₹29 Cr₹46 Cr-₹93 Cr-₹4 Cr-₹2 Cr
-₹13 Cr₹70 Cr₹6 Cr-₹2 Cr-₹29 Cr
₹78 Cr₹8 Cr₹1 Cr₹3 Cr₹32 Cr
₹65 Cr₹78 Cr₹8 Cr₹1 Cr₹3 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)197.00
Volume (₹)43.85 L
High (₹)204.98
Upper Circuit235.71
Low (₹)192.50
Lower Circuit157.15
Prev Close196.43
52W High (₹)204.98
Price200.36
52W Low (₹)67.19

Share Market Cap & Key Ratios Overview

M.Cap (₹)5753.14 Cr
Div. Yield (%)0.10
PE Ratio34.22
Debt to Equity0.07
Price to Book1.19
Book Value61.27
EPS (TTM)5.73
Face Value2.00
ROE (%)7.90

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
IOLCPNSE
LTP
1W Low
1W High
Market cap (₹)
1899.7-20.3 (-1.06%)
1896.80
1984.80
4,56,833Cr
9149-90 (-0.97%)
9087
9467
2,45,426Cr
4828.5-221.5 (-4.39%)
4827
5066
1,87,320Cr
1129.6-61.4 (-5.16%)
1125.10
1187
1,13,217Cr
1377.9-45.6 (-3.20%)
1376
1426.10
1,12,212Cr
1847-91.5 (-4.72%)
1811.70
1949
1,01,155Cr
2110.5-61 (-2.81%)
2110.30
2192
97,626Cr
2335.9-47 (-1.97%)
2334
2419.20
96,859Cr
1158.4-19.6 (-1.66%)
1154.40
1179.90
96,406Cr
1653.6+8.3 (0.50%)
1622.60
1717
93,614Cr
200.36+5.41 (2.78%)
186
204.98
5,753Cr

IOL Chemicals And Pharmaceuticals Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹111.67Cr; with other income of ₹8.18Cr, profit before interest and tax came to ₹90.33Cr. Interest expense was ₹3.64Cr; PBT before exceptional items stood at ₹86.69Cr. Cost mix (full year): raw materials ₹1505.63Cr; employee cost ₹248.26Cr; depreciation ₹21.34Cr; other expenses ₹652.77Cr. Basis: consolidated annual results.

IOL Chemicals And Pharmaceuticals Ltd Quaterly Results Key Takeaways

IOL Chemicals And Pharmaceuticals Ltd reported ₹756.26Cr total income from operations in Jun 2026, softer than ₹619.45Cr in Mar 2026 but higher than ₹551.69Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹111.67Cr; with other income of ₹8.18Cr, profit before interest and tax came to ₹90.33Cr. Interest expense was ₹3.64Cr, taking profit before tax to ₹86.69Cr. After tax of ₹22.29Cr, profit after tax stood at ₹64.4Cr (vs ₹53.16Cr in Mar 2026 and ₹33.93Cr in Jun 2025).